Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Think Research Corporation V.THNK

Think Research Corporation is a Canada-based company that offers digital health software solutions. It is a provider of cloud-based data, knowledge, and software solutions primarily delivered as software-as-a-service (SaaS) to healthcare delivery systems and the practitioners that they support. Its operations are organized into three lines of business: Software and Data Solutions, Clinical Research, and Clinical Services. Its SaaS solutions help patients find, navigate, and connect to health services across large governments and payer clients, while also ensuring safety for prescribed medications at pharmacies. Through its wholly owned subsidiary, BioPharma Services Inc., the Company provides research data and analysis derived from Phase I clinical trials, bioequivalence studies and bioanalytical services. Its clinics act as a test bed for its software and technology, transforming them with digital solutions that optimize clinical outcomes, streamline workflows, and optimize billing.


TSXV:THNK - Post by User

Comment by Possibleidiot01on Nov 27, 2023 7:45pm
94 Views
Post# 35755386

RE:It's Time for New Management

RE:It's Time for New ManagementTo me , the question is here is what has management been doing all year? Maybe that should include all the time since April 25,2022 when Beedie Capital stepped up? Why are revenues and costs continuing to be out of whack?

"Operating expenses declined to $13.9 million in Q3 and $42.1 million in the year-to-date 2023 representing a decrease of 1% and 5% over the prior year periods."

Supposedly the focus has been on operational rationalization . The results so have the closure of a clinic , St. Louis  which was closed in late September which should produce $2 million dollars of savings relatively quickly as Missouri is a "Right to Work" with no severance costs and another clinic was sold and immaterial to results.

It just seems like watching  a little leak erode the dam and then when it gets big hurriedly hauling a dump truck to the leak. This is reactive management , not proactive management.

Interesting tidbit from the conference call when the Desjardins analyst was the best . Pharmapod has very limited competition in the market place ...... part of a fire sale?
<< Previous
Bullboard Posts
Next >>